Zymeworks Inc. presented an update on its business strategy and operations at the JPM Healthcare Conference. The company highlighted its focus on expanding its royalty and asset portfolio, leveraging both asset-based pipeline partnerships and platform discovery collaborations. Key commercial partners and programs were discussed, including zanidatamab and several early-stage oncology assets such as antibody-drug conjugates and T-cell engagers. Zymeworks reported cash resources exceeding $270 million and outlined potential milestone and royalty payments from partnered products. The company stated that its current financial position is expected to fund operations beyond 2028. Additionally, Zymeworks announced a share repurchase plan and reported $103 million in revenues for 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.